Suraksha Diagnostic Ltd (SURAKSHA)

📊 Quarterly Results (₹ Cr)

Revenue grew sequentially from ₹78 crore (Dec 2025) to ₹88 crore (Jun 2026), with OPM expanding from 16.2% to 21.9% and NP rising from ₹7 crore to ₹13 crore, reflecting improving operational leverage. PAT margin increased to 14.7% in Q1 FY27 from prior-year levels, supported by margin-enhancing initiatives and higher-margin genomics revenue. EBITDA margin improved to 36.0% in Q1 FY27 from 34.0% in the prior year, indicating better cost control and scale benefits. The company added 11 new diagnostic centers in FY27, contributing to top-line growth and network density. Despite modest absolute cash flows, the trend in profitability and margin expansion aligns with management’s focus on scaling high-growth segments like genomics and AI-enabled diagnostics.

🔮 Management Outlook & What's Next

Management expects sustained momentum in Suraksha Genomics, projecting continued double-digit growth as it scales specialized testing services. Expansion plans include adding 11 new diagnostic centers in FY27 and deepening presence in Eastern and North-Eastern India. The company is investing in advanced infrastructure, including AI-enabled platforms and rapid diagnostic tools like Genexus, to capture value in the 12% CAGR Indian diagnostics market. The 21st AGM on 22 September 2026 will be pivotal for approving financials, declaring dividends, and outlining strategic direction. Management emphasizes long-term growth through technological innovation and geographic diversification, supported by a disciplined capital allocation approach.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet reflects a strong capital structure with negligible net debt (debt-to-equity of 0.43) and consistent equity base of ₹10 crore, indicating conservative leverage and financial stability. Reserves have grown steadily from ₹201 crore (Mar 2025) to ₹234 crore (Mar 2026), suggesting retained earnings and prudent reinvestment. Borrowings remain low and stable, supporting a deleveraging trajectory despite expansion. This financial discipline enables the company to fund growth internally while maintaining flexibility for strategic investments or downturn resilience.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Institutional interest remains stable, with FII holding at 13.47% (Q1FY27) and DII at 23.22%, indicating sustained confidence from both domestic and foreign investors. Promoter holding is steady at 49.1%, with no signs of dilution or selling pressure. The growing number of shareholders (64,866 in Q1FY27) suggests broadening retail participation. No pledging or significant changes in shareholding patterns are evident, reflecting confidence in long-term fundamentals and governance continuity.

⚖️ Peer Comparison — Healthcare

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Geographic concentration in Eastern India exposes the company to regional economic or regulatory disruptions. 2. Low contribution from consultation services (only 7%) limits revenue diversification and margin resilience. 3. Integration risks from recent acquisitions like Fetomat Wellness could strain operations or capital. 4. Execution risks in scaling new centers and Genexus platform adoption may delay ROI. Despite strong margins, revenue growth remains dependent on network expansion pace and market penetration in underserved regions.

📋 Recent Filings

• Announcement2026-09-28Suraksha Diagnostic Limited announced that its trading window will close on 1 October 2026 and remain shut until 48 hours after the release of unaudit…
• 🟡 voting results2026-09-24Suraksha Diagnostic Limited held its 21st AGM on September 22, 2026 via video conference, approving the audited standalone and consolidated financial …
• 🟡 Board Meeting2026-09-23Suraksha Diagnostic held its 21st AGM on September 22, 2026, approving audited standalone and consolidated financial statements for FY2025-26, declari…
• 🟡 Board Meeting2026-09-22Suraksha Diagnostic held its 21st AGM on September 22, 2026, approving audited standalone and consolidated financial statements for FY2025-26, declari…
• 🔴 annual report2026-08-27Suraksha Diagnostic Limited reported FY2025-26 revenue of ₹31,041.41 crore and PAT of ₹3,406.22 crore, driven by expansion to 68 diagnostic centers an…
• 🟡 Board Meeting2026-08-27Suraksha Diagnostic announced its 21st Annual General Meeting will be held on 22 September 2026 via video conference, with record date for dividend on…
• 🟡 Board Meeting2026-08-27The 21st Annual General Meeting of Suraksha Diagnostic Ltd is scheduled for 22 September 2026, where shareholders will vote on adopting the FY 2025-26…
• Announcement2026-08-17Suraksha Diagnostic reported strong Q1 FY'27 results with 21% revenue growth, 28% EBITDA growth, and 40% PAT growth, driven by expansion to 72 centers…
• Announcement2026-08-13Suraksha Diagnostic Limited announced that the audio recording of its earnings call held on 13 August 2026 at 11:30 a.m. IST is now available on its w…
• 🟡 Board Meeting2026-08-12Suraksha Diagnostic Limited announced the outcome of its board meeting held on 12 August 2026, approving unaudited standalone and consolidated financi…

🧠 Analyst's Read

Suraksha Diagnostic is executing a disciplined growth strategy with improving profitability, strong returns, and strategic investments in genomics and infrastructure. The company’s financial health and margin expansion are compelling, but investors should monitor execution risks in geographic expansion and acquisition integration. The upcoming AGM and Genexus scalability will be key near-term catalysts.

Based on filing content and financial data. Not a recommendation.